Browse medicines, page 29 of 37

Use listed on the medicine record

Insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings [see Clinical Studies

Use listed on the medicine record

Use with magnetic resonance imaging (MRI) for evaluation of lung ventilation

Use listed on the medicine record

Cough, sneezing, runny nose, occasional headache, nausea, or weakness

Use listed on the medicine record

The symptomatic relief of cough

Use listed on the medicine record

The gradual bleaching of hyperpigmented skin conditions age and liver spots, freckles, and other unwanted areas of melanin hyperpigmentation

Use listed on the medicine record

Moderate-to-severe plaque psoriasis

Use listed on the medicine record

Acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen

Use listed on the medicine record

FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )

Use listed on the medicine record

Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome…

Use listed on the medicine record

Isoniazid tablets, USP are recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. Isoniazid tablets, USP are recommended as preventive therapy for the following groups, regardless of age.

Use listed on the medicine record

INSTRUCTIONS FOR USE 1. Cleanse and moisturize. 2. Apply the mask evenly to the face, avoiding eyes and mouth. 3. Let dry for 15 mins, then sleep. 4. Remove mask or rinse next morning.

Use listed on the medicine record

Community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms

Use listed on the medicine record

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Use listed on the medicine record

HIV-1 infection

Use listed on the medicine record

Metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy

Use listed on the medicine record

as Antacid • relieves • heartburn • sour stomach • acid indigestion • and upset stomach associated with these symptoms Uses as Saline Laxative • for relief of occasional constipation (irregularity) • this product generally produces bowel movement in 1/2 to 6 hours

Use listed on the medicine record

Infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair

Use listed on the medicine record

Cholestatic pruritus

Use listed on the medicine record

LIVTENCITY ® is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ] .

Use listed on the medicine record

Moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension

Use listed on the medicine record

Idiopathic heavy menstrual blood loss

Use listed on the medicine record

INDICATIONS For the temporary relief of diarrhea, gas, cramping, fatigue, minor joint pain or swelling, or occasional headache due to sensitivity to phenolic compounds found in foods or other products.*

Use listed on the medicine record

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Use listed on the medicine record

POLOCAINE (Mepivacaine HCl Injection, USP), is indicated for production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks. The routes of administration and indicated concentrations for mepivacaine are: local infiltration 0.5% (via dilution) or 1 % peripheral nerve blocks 1% and 2% epidural block 1%, 1.5%, 2% caudal block 1%, 1.5%, 2% See DOSAGE AND ADMINISTRATION for additional information.

Use listed on the medicine record

Anxiety disorders or for the short-term relief of the symptoms of anxiety

Use listed on the medicine record

BIOCORNEUM ® can reduce the appearance of scars and is ideal for use on any intact skin surface, including skin that flexes (such as joints) and areas exposed to sun (such as the face and hands).

Use listed on the medicine record

The diagnosis of bronchial airway hyperreactivity

Use listed on the medicine record

Discomfort associated with acute, painful musculoskeletal conditions

Use listed on the medicine record

Methohexital Sodium for Injection can be used in adults as follows: 1.For intravenous induction of anesthesia prior to the use of other general anesthetic agents. 2.For intravenous induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for short surgical procedures; Methohexital Sodium for Injection may be given by infusion or intermittent injection.

Use listed on the medicine record

Krx Aesthetics PD-13 Therapy, which includes 13% of Methyl Aminolevulinate HCI, is developed to maximize the client’s satisfaction for PDT(Photo Dynamic Therapy).